中医药是中国优秀传统文化的代表，经典名方作为中药复方的典型代表，在药品注册方面有了新的突破，但是，也应注意到由此带来的研究挑战，尤其是非临床安全性研究方面的挑战，另外在临床定位、药理基础研究方面，研发者和生产单位还有很长的路要走，应提前为经典名方的长远发展做足准备。

Traditional Chinese medicine is the representative of Chinese excellent traditional culture, and it's congratulated that the classical herbal formulae get a new breakthrough in drug registration as the typical representative of traditional Chinese medicine formula. Meanwhile, we should also pay attention to the challenge of research in the new situation, especially for nonclinical safety research. Otherwise, there are so many job to do for research institutions and pharmaceutical companies on the studies of clinical orientation and pharmacology materia basis. It is important to prepare early beause it is a long-term of the development of the classic herbal formulae.